Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation

被引:22
作者
Baan, CC
Balk, AHMM
van Riemsdijk, IC
Vantrimpont, PJMJ
Maat, APWM
Niesters, HGM
Zondervan, PE
van Gelder, T
Weimar, W
机构
[1] Erasmus MC, Dept Internal Med, NL-3000 DR Rotterdam, Netherlands
[2] Erasmus MC, Dept Cardiol, NL-3000 DR Rotterdam, Netherlands
[3] Erasmus MC, Dept Thorac Surg, NL-3000 DR Rotterdam, Netherlands
[4] Erasmus MC, Diagnost Inst Mol Biol, NL-3000 DR Rotterdam, Netherlands
[5] Erasmus MC, Dept Pathol, NL-3000 DR Rotterdam, Netherlands
关键词
D O I
10.1097/01.TP.0000063937.53702.97
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. To define whether immunosuppressive agents that block the interleukin (IL)-2 pathway could prevent activation-induced cell death of activated T cells in the graft, we measured expression of IL-2, IL-2 receptor a chain (CD25), IL-15, Fas, and Fas ligand by real time reverse transcription-polymerase chain reaction in cardiac allografts. Methods. We characterized the phenotype of the infiltrating cells (CD3, CD68, CD25) by immunohistochemistry. The proportion of apoptotic graft-infiltrating cells was determined by TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) staining. We analyzed endomyocardial biopsy specimens from cardiac allograft recipients who were treated with anti-CD25 monoclonal antibody (mAb) induction therapy (daclizumab) or with matching placebo in combination with cyclosporine, steroids, and mycophenolate mofetil. Results. Treatment with anti-CD25 mAb affected the number of infiltrating CD3 and CD68 cells and the IL-2-regulated apoptotic pathway. During anti-CD25 mAb treatment, significantly lower intragraft IL-2 and CD25 mRNA transcription levels and decreased numbers of CD25(+) T cells were found compared with the levels measured in endomyocardial biopsy specimens from placebo-treated patients (5- to 10-fold, P=0.002 and P<0.0001, respectively). In these samples the intragraft mRNA expression levels of IL-15 were also lower (P=0.02). Inhibition of the IL-2 pathway by anti-CD25 mAb therapy was accompanied by reduced mRNA and protein of Fas ligand and not by reduced Fas expression (P=0.001 and P=0.03). TUNEL staining revealed that the proportion of graft-infiltrating cells was lower in the anti-CD25 mAb patient group than the proportion of apoptotic cells in patients receiving placebo (P=0.06). Conclusion. Our data suggest that immunosuppressive agents that affect the IL-2 pathway hinder the mechanism of activation-induced cell death by which the immune system eliminates alloreactive cells.
引用
收藏
页码:1704 / 1710
页数:7
相关论文
共 24 条
[1]   Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation [J].
Baan, CC ;
Knoop, CJ ;
van Gelder, T ;
Holweg, CTJ ;
Niesters, HGM ;
Smeets, TJM ;
van der Ham, F ;
Zondervan, PE ;
Maat, LPWM ;
Balk, AHMM ;
Weimar, W .
TRANSPLANTATION, 1999, 67 (06) :870-876
[2]   IL-7 and IL-15 bypass the immunosuppressive action of anti-CD25 monoclonal antibodies [J].
Baan, CC ;
Boelaars-van Haperen, MJAM ;
van Riemsdijk, IC ;
van der Plas, AJ ;
Weimar, W .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (03) :2244-2246
[3]   Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-β1 type I receptor expression [J].
Baan, CC ;
van Riemsdijk-van Overbeeke, IC ;
Balk, AHMM ;
Vantrimpont, PMAJ ;
Mol, WM ;
Knoop, CJ ;
Niesters, HGM ;
Maat, LPWM ;
Weimar, W .
CLINICAL TRANSPLANTATION, 2001, 15 (04) :276-283
[4]   Intragraft cytokine gene expression: implications for clinical transplantation [J].
Baan, CC ;
Weimar, W .
TRANSPLANT INTERNATIONAL, 1998, 11 (03) :169-180
[5]   Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection [J].
Baan, CC ;
van Gelder, T ;
Balk, AHMM ;
Knoop, CJ ;
Holweg, CTJ ;
Maat, LPWM ;
Weimar, W .
TRANSPLANTATION, 2000, 69 (03) :331-336
[6]   Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. [J].
Beniaminovitz, A ;
Itescu, S ;
Lietz, K ;
Donovan, M ;
Burke, EM ;
Groff, BD ;
Edwards, N ;
Mancini, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (09) :613-619
[7]  
Dai ZH, 1999, J IMMUNOL, V163, P3131
[8]   Daclizumab (Zenapax®) inhibits early interleukin-2 receptor signal transduction events [J].
Goebel, J ;
Stevens, E ;
Forrest, K ;
Roszman, TL .
TRANSPLANT IMMUNOLOGY, 2000, 8 (03) :153-159
[9]   The Jak-STAT pathway [J].
Imada, K ;
Leonard, WJ .
MOLECULAR IMMUNOLOGY, 2000, 37 (1-2) :1-11
[10]  
*INT SOC HEART TRA, 1990, J HEART TRANSPLANT, V9, P587